Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Cerilliant
Baxter
Healthtrust
Farmers Insurance
Queensland Health
Deloitte
Harvard Business School
Johnson and Johnson
Chubb

Generated: August 17, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Cyclic peptide antifungal agents and process for preparation thereof
Abstract:Provided are compounds of the formula (1): ##STR1## wherein R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --; R" and R'" are independently methyl or hydrogen; R adn R.sup.y are independently hydroxy or hydrogen; R.sub.1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R.sub.7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R.sub.2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.
Inventor(s): Burkhardt; Frederick J. (Indianapolis, IN), Debono; Manuel (Indianapolis, IN), Nissen; Jeffrey S. (Indianapolis, IN), Turner, Jr.; William W. (Bloomington, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:10/087,088
Patent Claims: 1. A pharmaceutical formulation comprising a compound having the following formula: ##STR255##

and a pharmaceutically acceptable carrier.

2. A method for inhibiting parasitic activity comprising contacting a formulation of claim 1 with a parasite.

3. A method of inhibiting fungal activity comprising contacting a formulation of claim 1 with a fungus.

4. A method of inhibiting the growth of organisms responsible for opportunistic infections in immunosuppressed individuals comprising administering a formulation of claim 1 to said individual.

5. A method of inhibiting the growth of Pneumocystis carinii comprising contacting a formulation of claim 1 with Pneumocystis carinii.

6. A pharmaceutical formulation comprising a compound represented by the formula ##STR256##

wherein R is --O(CH.sub.2).sub.3 CH.sub.3, --O(CH.sub.2).sub.4 CH.sub.3, --O(CH.sub.2).sub.5 CH.sub.3, --O(CH.sub.2).sub.2 O(CH.sub.2).sub.3 CH.sub.3, or --O(CH.sub.2).sub.2 OC(CH.sub.3).sub.3 and a pharmaceutically acceptable carrier.

7. The formulation of claim 6, wherein R is --O(CH.sub.2).sub.4 CH.sub.3.

8. A method for inhibiting parasitic activity comprising contacting a formulation of claim 6 with a parasite.

9. The method of claim 8, wherein R is --O(CH.sub.2).sub.4 CH.sub.3.

10. A method of inhibiting fungal activity comprising contacting a formulation of claim 6 with a fungus.

11. The method of claim 10, wherein R is --O(CH.sub.2).sub.4 CH.sub.3.

12. A method of inhibiting the growth of organisms responsible for opportunistic infections in immunosuppressed individuals comprising administering a formulation of claim 6 to said individual.

13. The method of claim 12, wherein R is --O(CH.sub.2).sub.4 CH.sub.3.

14. A method of inhibiting the growth of Pneumocystis carinii comprising contacting a formulation of claim 6 with Pneumocystis carinii.

15. The method of claim 14, wherein R is --O(CH.sub.2).sub.4 CH.sub.3.

16. A pharmaceutical formulation comprising a compound represented by the formula ##STR257##

and a pharmaceutically acceptable carrier.

17. A pharmaceutical formulation comprising a pharmaceutically acceptable salt of the formulation according to claim 16.

18. A method for inhibiting parasitic activity comprising contacting a formulation of claim 16 with a parasite.

19. A method of inhibiting fungal activity comprising contacting a formulation of claim 16 with a fungus.

20. A method of inhibiting the growth of organisms responsible for opportunistic infections in immunosuppressed individuals comprising administering a formulation of claim 16 to said individual.

21. A method of inhibiting the growth of Pneumocystis carinii comprising contacting a formulation of claim 16 with Pneumocystis carinii.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Medtronic
Deloitte
Julphar
Moodys
Merck
Novartis
Mallinckrodt
Citi
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot